Determining risk of prostate tumor aggressiveness
AssigneeThe Regents of the University of California
InventorsPamela PARIS, Matthew COOPERBERG, Peter CARROLL
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods, computer products, computer-implemented methods, and systems for predicting the probability or risk of prostate cancer recurrence and tumor aggressiveness in a patient. The method is based, in part, on the patient's risk profile that includes the presence/degree of specific copy number variations and predictive clinical factors. The methods and systems can be used to aid in treatment selection.
Claims6
-15. (canceled)
A method for evaluating a biopsy sample to determine a likelihood that a prostate tumor will be aggressive:
- (a) detecting copy numbers at a set of genomic regions or portions thereof in a nucleic acid sample from a prostate tumor obtained from a human patient, wherein the set of genomic regions or portions thereof comprises genomic regions or portions thereof at human chromosomes 3q26.2, 3q26.32, 3q26.3, 5p15.1, 7p22.3, 7q11.22, 7q11.23, 7q22.1, 7q31.31, 9q34.1, 11p15.4, 17q21.33, 17q25.3, 22q13.1, 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14.3 and 16q23.1;
- (b) scoring each genomic region or portion thereof as diseased or normal, wherein the scoring is determined based on the copy number in the nucleic acid sample from the prostate tumor compared to a reference normal copy number of non-cancerous tissue;
- and the genomic region is scored as diseased if there is an increase in copy number at the genomic region or portion thereof located at human chromosome 3q26.2, 3q26.32, 3q26.3, 5p15.1, 7p22.3, 7q11.22, 7q11.23, 7q22.1, 7q31.31, 9q34.1, 11p15.4, 17q21.33, 17q25.3, or 22q13.1 in the nucleic acid sample from the biopsy compared to the reference normal copy number, or if there is a decrease in copy number at the genomic region or portion thereof located at human chromosome 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14.3 or 16q23.1 in the nucleic acid sample from the biopsy compared to reference copy number;
- (c) assigning values to each CAPRA-S clinical factor;
- and
- (d) determining a risk score for tumor aggressiveness by statistical analysis that combines copy number scores generated in (b) and CAPRA-S clinical factor values generated in (c) as continuous and individual variables.
A computer-implemented method for determining a risk of prostate tumor aggressiveness:
- (a) receiving, at one or more computer system(s), information about a set of copy numbers determined from a tumor sample of a prostate tumor for a set of genomic regions or portions thereof, wherein the set of genomic regions or portions thereof comprises genomic regions or portions thereof at human chromosomes 3q26.2, 3q26.32, 3q26.3, 5p15.1, 7p22.3, 7q11.22, 7q11.23, 7q22.1, 7q31.31, 9q34.1, 11p15.4, 17q21.33, 17q25.3, 22q13.1, 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14.3 and 16q23.1;
- (b) performing, with one or more processors associated with the computer system(s), a comparison of the set of copy numbers in the tumor sample to a set of reference copy numbers to score the genomic region or portions thereof as diseased or normal, wherein the genomic region is diseased if there is an increase in copy number at the genomic region or portion thereof at human chromosome 3q26.2, 3q26.32, 3q26.3, 5p15.1, 7p22.3, 7q11.22, 7q11.23, 7q22.1, 7q31.31, 9q34.1, 11p15.4, 17q21.33, 17q25.3, or 22q13.1 in the tumor sample compared to the reference copy number, and if there is a decrease in copy number at the genomic region or portion thereof at human chromosome 4p13, 5q13.1, 5q14.3, 5q21.1, 5q21.2, 5q21.3, 5q23.1, 6q14.1, 6q21, 8p22, 8p21.2, 8p12, 10q23.31, 13q14.11, 13q14.13, 13q14.2, 13q14.3 or 16q23.1 in the tumor sample compared to the reference copy number;
- (c) receiving, with one or more processors associated with the computer system(s), values for each CAPRA-S clinical factor;
- and
- (d) generating, with one or more processors associated with the computer system(s), a risk factor score by statistical analysis that combines copy number scores generated in (b) and CAPRA-S clinical factor values generated in (c) as continuous and individual variables.
Dependencies are inferred from the claim text.